Finanzen von BioXcel Therapeutics Inc (BTAI)BTAIBioXcel Therapeutics Inc

Evaluating the bottom line, BioXcel Therapeutics Inc maintains a gross margin of 87.91%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -5600.55%, while the net margin is -8084.07%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively BTAI converts its operational activities into shareholder value.

In the context of the broader market, BTAI competes directly with industry leaders such as APUS and CVKD. With a market capitalization of $5.68M, it holds a significant position in the sector. When comparing efficiency, BTAI's gross margin of 87.91% stands against APUS's N/A and CVKD's N/A. Such benchmarking helps identify whether BioXcel Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company reported a total revenue of $182,000 in Q2 2026 but has consistently posted significant net income losses, including a loss of $14.7 million in the same quarter. The gross margin has fluctuated, with a recent high of 87.91% in Q2 2026, but overall financial performance remains weak.